46 citations
,
October 2018 in “JCI insight” In this study, the researchers found that treatment with the JAK inhibitor tofacitinib in alopecia areata patients may reduce clonal CD8+ T cell expansions but does not eliminate them entirely, which could contribute to disease relapse.
1 citations
,
November 2018 in “immuneACCESS” This study found that in alopecia areata, treatment with the oral JAK-inhibitor tofacitinib decreased clonally expanded CD8⁺ T cells in the scalp, but many expanded clones did not completely disappear, potentially leading to relapse after stopping treatment.
22 citations
,
September 2020 in “The journal of investigative dermatology/Journal of investigative dermatology” This review highlights the possible role of T regulatory cells in the immune-related mechanisms of alopecia areata but reports no new clinical findings.
January 2026 in “British Journal of Dermatology” In this study, distinct immune and cellular profiles were observed in adults with atopic dermatitis associated with high levels of Staphylococcus aureus, including increased proinflammatory T cells and markers of skin barrier impairment, pointing to potential therapeutic targets for managing these interactions.
This study provides a detailed analysis of cell subpopulations in a mouse model of wound-induced hair follicle regeneration, revealing specific cellular dynamics and heterogeneity that may influence hair follicle neogenesis.
